VogelsteinScience15Apr13.ppt Updated: April 15, 2013 Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science,

Slides:



Advertisements
Similar presentations
Medical Mystery Patient X. Symptoms 0 Patient’s Symptoms: 0 Possible Diseases/Disorders: 0 Final Diagnosis:
Advertisements

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.
Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Lessons from Hereditary Colorectal Cancer
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
By: Katie Adolphsen, Robin Aldrich, Brandon Hu, Nate Havko.
NF2 = gene Merlin = protein…a.k.a. schwannomin Tumor Suppressor Tumor suppressive ability comes from partial inhibition of Ras/Rac signaling (phosphorylates.
Cell Signaling Lecture 10.
Resistance to TK inhibitors: KIT and PDGFRA Maria Debiec-Rychter, M.D., Ph.D. Center for Human Genetics, KULeuven, Belgium ESMO meeting Milan, May 13th,
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
Tumor Supressor Gene Non-functional TSG Mutations increasing risk of cancer “Loss of function” mutation Proto-oncogene Oncogene (Hyperactive or unregulated.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Is phosphorylation site disruption associated with cancer? Maricel G. Kann (University of Maryland, Baltimore County) Matthew E. Mort (Indiana University.
Calculus and Cancer Drug Development Studies Stephan Gysin, PhD UCSF Helen Diller Family Comprehensive Cancer Center.
Approach to a Mass of Unknown Significance Location Kinetics Systemic Manifestations.
Cancer &Oncogenes. Objectives Define the terms oncogene, proto-oncogenes and growth factors giving examples. Describe the mechanisms of activations of.
Colorectal Cancer Update Patient Perspectives on Colorectal Cancer Section 2 The Initial Diagnosis, Consultation with a Medical Oncologist.
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: The.
C-Kit is an Oncogene first found in a Feline Retrovirus Besmer, P., J. E. Murphy, P. C. George, F. Qui, P. J. Bergold, L. Lederman, H. W. Snyder Jr., D.
Cancer Genome Landscapes
Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):
CAP Cancer BioMarker Reporting Committee Biomarker - Problem, ROI and Scope College of American Pathologists’ Biomarker Reporting Committee Problem 1.Clinicians.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Biology of Cancer Weeks 1 Introduction and 2 RTKs Dr. Michael Chorney Susquehanna Medicine and Health Science Magnet February 17 th -28 th, 2014.
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.
Big Data in Genomics, Diagnostics, and Precision Medicine
Samsung Genome Institute Samsung Medical Center
The Department of Biochemistry & Molecular Biology
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma  Matti Annala, Lucia Nappi,
Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.
Gatekeeper, caretaker, and landscaper mutations
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Inhibitor of MAP kinase activation blocks colon cancer growth
Chapter 17: Regulation of cell number
Figure 1 Current treatments for PNETs
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Figure 4 Possible combination therapies CDK4/6 inhibitors
Cancer Genomics: The Road Ahead
Immunotherapy: The Path to Win the War on Cancer?
Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?
Nat. Rev. Urol. doi: /nrurol
Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?
Let to development of a class of antibodies (organic molecules) that are known as immune checkpoint inhibitors which are now used for cancer therapies.
Toru Furukawa  Clinical Gastroenterology and Hepatology 
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Emerging Themes in Biology: Hints for the Future
The Antisense Transcriptomes of Human Cells
Detection rate for EGFR mutations in cfDNA.
Nat. Rev. Nephrol. doi: /nrneph
The RAF Inhibitor Paradox Revisited
Clinical courses of patients.
Overview of the complex interactions among molecular classifications of TNBC based on genomic, transcriptomic, proteomic, epigenomic, and immune characterization.
Genetic landscape of salivary duct carcinoma.
(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.
RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Mutations.
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone?  Alvaro Leone, BSc.D 
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Detection and localization of surgically resectable cancers with a multi-analyte blood test by Joshua D. Cohen, Lu Li, Yuxuan Wang, Christopher Thoburn,
Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.
The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.
Simplified BRAF signaling network.
Location of the ER mutations and frequencies per cohort.
Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.
Frequently mutated genes in colorectal cancer.
Presentation transcript:

VogelsteinScience15Apr13.ppt Updated: April 15, 2013 Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science, Vol. 339, March 29, 2013, pp 1546 – 1548 Bert Vogelstein, Nickolas Papadopoulos, Victor Velculescu, Shibin Zhou, Luis Diaz, Kenneth W. Kinzler Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore

Number of somatic mutations associated with cancers in patients

From 5 or 10 to 130 to 700 mutations per tumor

(Insertions & deletions) ( Single base substitutions )

Signaling Pathways Affected In Cancers

Pathway Anomalies in Progression in Colo-Rectal Cancer

The RAS Pathway as a representative signaling pathway affected by cancer mutations and approaches to therapy based on RAS pathway anomalies RTK = receptor tyrosine kinase